Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 10 of 10« First...678910

Ear infection drug succeeds in late-stage trial

Drug developer Otonomy Inc. said its drug to treat acute otitis externa (AOE), an infection in the outer ear canal, met the main goal in a late-stage trial.

Read More »

Mark Heinold Joins TrialScope as New Chief Executive Officer

    Industry Veteran to Lead High Growth Technology Team          JERSEY CITY, N.J., Jan. 5, 2017 /PRNewswire/ — TrialScope, the global leader in managed compliance solutions for clinical trial disclosure, today announced that the Board of Directors have appointed Mark Heinold as chief executive officer. Mr. Heinold joins TrialScope with over […]

Read More »

Tiny Boston Biotech Pieris Nabs $570 Million+ Cancer Deal With French Powerhouse Servier

Pieris, based in Boston, and Servier Forge, located in Suresnes, France, signed a broad collaboration deal focused on immuno-oncology.

Read More »

Lilly CEO Shakes Up Leadership Structure

Eli Lilly is looking to begin 2017 with a series of organizational changes that includes changes in some leadership roles.

Read More »

SoCal Biotech Arena Officially Bails on Weight Loss Drug to Focus on New Products

Arena Pharmaceuticals is shedding some unwanted weight. The company is selling its weight-loss drug Belviq to Eisai Co. Ltd., which has marketing rights to Belviq throughout much of the world.

Read More »

Pence says repealing Obamacare ‘first order of business’

President-elect Donald Trump has made repealing President Barack Obama’s signature healthcare law the “first order of business” and intends a smooth transition to a “market-based” medical insurance system, said Vice President-elect Mike Pence.

Read More »

Novartis Athens Offices Raided in Bribery Probe, Exec Threatens With Suicide at Nearby Hotel

Another Novartis AG office has been raided by authorities in connection to bribery allegations. This time authorities in Greece searched electronic data and files following the submission of media reports to that nation’s justice department.

Read More »

Gilead poaches Novartis cancer specialist Riva

Gilead Sciences has hired a top cancer specialist from Swiss drugmaker Novartis as the U.S. healthcare group sharpens its focus on oncology.

Read More »

Nivalis Begins Exploring Strategic Alternatives and Streamlining Ops After Clinical Trial Setback

Nivalis Therapeutics announced that it is evaluating “strategic alternatives,” which may include the possibility of an acquisition, merger or other strategic transaction.

Read More »

As Promised, Allergan Unveils Single-Digit Price Hikes for 9 Brand Name Drugs

In September 2016, Allergan’s Chief Executive Officer Brent Saunders publicly vowed to keep price increases on the company’s drugs under 10 percent in 2017. Saunders kept his word. The Irish company announced nine older drugs would see price increases of 9 to 9.5 percent–staying under that 10 percent mark.

Read More »

Judge reduces award in J&J hip implants case

A U.S. judge almost halved the award in a December 2016 jury verdict that ordered J&J and DePuy Orthopaedics to pay $1+ billion to plaintiffs in six lawsuits.

Read More »

Sanofi, Regeneron lose bid to overturn Amgen win in patent case

A federal judge refused to throw out a court verdict upholding two Amgen patents related to its cholesterol drug, a defeat for Sanofi and Regeneron Pharmaceuticals, which make a rival drug.

Read More »

Many U.S. kids live far from child surgery specialists

More than 10 million U.S. children do not live near a pediatric anesthesiologist, a doctor who specializes in sedating children during surgery, according to a recent study.

Read More »

Inotek’s glaucoma treatment fails late-stage study

Inotek Pharmaceuticals Corp. said its experimental glaucoma treatment failed a late-stage study, citing a stronger-than-expected placebo effect.

Read More »

Listen Up Researchers: Versant Ventures To Fund Two Dozen Biotech Startups With $400 Million

Versant Ventures closed on its newest fund, Versant Venture Capital VI, with $400 million it plans to invest in 20 to 25 biotechnology companies in the U.S., Canada and Europe. The first investment is expected in the first quarter of 2017.

Read More »

How Allergan CEO’s New Model Will be Tested in 2017

In the first half of 2016, investors were watching the Pfizer-Allergan merger deal, which was scuttled in April by the U.S. Treasury Department. Part of the fascination, besides the fact it would have created the largest pharmaceutical company in the world, was over how in about seven years Allergan’s CEO Brent Saunders had gone from heading the consumer health division at Schering-Plough to being the chief-executive-in-waiting for the biggest pharma company on the planet.

Read More »

3 Quiet Biotechs Ready to Make Some Noise in 2017

There are plenty of “brand name” biotech companies out there that everyone interested in biopharma knows about — Shire, Gilead Sciences, Genentech, Biogen and so on — but there are several smaller biotech companies that investors may not have heard of that are worth checking out. Keith Speights, writing for The Motley Fool, takes a look at three.

Read More »

Benefits of new cancer drugs vary widely

Drugs recently approved around the world to fight cancer increased patients’ overall survival, but benefits vary depending on the drug, a new study shows.

Read More »

New drug approvals fall to six-year low in 2016

2016 turned out to be a disappointing one for new drug approvals with the U.S. Food and Drug Administration clearing just 22 new medicines for sale, the lowest number since 2010 and sharply down on 2015’s tally of 45.

Read More »

Page 10 of 10« First...678910

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom